Pfizer acquired Trillium to gain access to two lead blood cancer therapies designed to block this signal and help the immune system destroy cancer cells.
The "story" behind this deal began decades earlier at University Health Network (UHN) and SickKids in Toronto. Researchers discovered a "do not eat me" signal (CD47) that cancer cells use to hide from the immune system. buy trillium
The deal was a massive win for Trillium shareholders; the purchase price of $18.50 per share was triple the stock's closing price just days before the announcement. 2. The Sci-Fi "Story": Jeff Lemire's Trillium Pfizer acquired Trillium to gain access to two
The request to "buy trillium" can refer to several distinct "stories"—from a massive multi-billion dollar corporate acquisition to a sci-fi epic spanning thousands of years. 1. The Corporate "Story": Pfizer’s $2.3 Billion Bet The deal was a massive win for Trillium
In August 2021, pharmaceutical giant announced its intent to buy Trillium Therapeutics for approximately $2.26 billion .